Full Press Release Details
IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best In Class PRMT5 Inhibitor for MTAP Deletion Solid Tumors.
IDYA
IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best In Class PRMT5 Inhibitor for MTAP Deletion Solid Tumors
Key Takeaway: IDEAYA Biosciences Announces IND Submission for IDE892, a Potential Best In Class PRMT5 Inhibitor for MTAP Deletion Solid Tumors
Price reaction · baseline $25.48 (2025-09-02 close) · hit after-hours · 6 other IDYA headline(s) in the window, move may be shared
day 0 close · peak
+1.1%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma